Dihydralazine
 | |
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| ATC code | |
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.006.914  |
| Chemical and physical data | |
| Formula | C8H10N6 |
| Molar mass | 190.210 g·mol−1 |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
  (what is this?) (verify) | |
Dihydralazine is a prescription drug[1] with antihypertensive properties.[2] It functions by combating the effects of adrenaline, and by expanding the blood vessels so as to enable smoother flow of blood by decreasing the pressure. It is generally administered orally, and is available in the form of tablets.[1] It belongs to the hydrazinophthalazine chemical class.[3] It has very similar effects to hydralazine.[3]
Side Effects
Contraindications
Contraindications to this drug include allergic reactions to this drug or to any of its components, ischemic heart diseases, coronary artery diseases, valvular stenosis, aortic aneurysms and pericarditis. Patients who have a previous medical history of kidney dysfunctions, liver damage, heart disorders and cerebro-vascular disorders must exercise caution while taking this medicine. Dihydralazine must not be prescribed to patients who are elderly, and to breastfeeding women. Caution must be exercised while prescribing this medicine to pregnant women.[1]
Other Important information on intake
When ending intake, you are recommended to withdraw gradually from this medicine, as opposed to abruptly ceasing its intake. Heartbeat problems and edema may occur as adverse effects.[1]
See also
References
- 1 2 3 4 5 6 7 8 9 10 11 12 Dihydralazine - Uses, Side Effects, Substitutes, Composition And More. (n.d.). Lybrate. Retrieved July 10, 2021, from https://www.lybrate.com/medicine/dihydralazine
- ↑ Stern HC, Matthews JH, Belz GG (October 1984). "Influence of dihydralazine induced afterload reduction on systolic time intervals and echocardiography in healthy subjects". British Heart Journal. 52 (4): 435–9. doi:10.1136/hrt.52.4.435. PMC 481656. PMID 6477782.
- 1 2 Bourreli B, Pinaud M, Passuti N, Gunst JP, Drouet JC, Remi JP (May 1988). "Additive effects of dihydralazine during enflurane or isoflurane hypotensive anaesthesia for spinal fusion". Canadian Journal of Anaesthesia. 35 (3 ( Pt 1)): 242–8. doi:10.1007/BF03010617. PMID 3383316.